CN115697410A - 用于治疗急性呼吸窘迫综合征的组合物和方法 - Google Patents

用于治疗急性呼吸窘迫综合征的组合物和方法 Download PDF

Info

Publication number
CN115697410A
CN115697410A CN202180043755.8A CN202180043755A CN115697410A CN 115697410 A CN115697410 A CN 115697410A CN 202180043755 A CN202180043755 A CN 202180043755A CN 115697410 A CN115697410 A CN 115697410A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
antibody
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180043755.8A
Other languages
English (en)
Chinese (zh)
Inventor
M·J·布鲁克斯
B·R·G·戈登
P·尼哈万
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adesa Biotechnology Research Co ltd
Original Assignee
Adesa Biotechnology Research Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adesa Biotechnology Research Co ltd filed Critical Adesa Biotechnology Research Co ltd
Publication of CN115697410A publication Critical patent/CN115697410A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202180043755.8A 2020-04-20 2021-04-20 用于治疗急性呼吸窘迫综合征的组合物和方法 Pending CN115697410A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063012786P 2020-04-20 2020-04-20
US202063012783P 2020-04-20 2020-04-20
US63/012783 2020-04-20
US63/012786 2020-04-20
US202063081662P 2020-09-22 2020-09-22
US63/081662 2020-09-22
PCT/CA2021/050544 WO2021212222A1 (en) 2020-04-20 2021-04-20 Compositions and methods for treatment of acute respiratory distress syndrome

Publications (1)

Publication Number Publication Date
CN115697410A true CN115697410A (zh) 2023-02-03

Family

ID=78270861

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180043755.8A Pending CN115697410A (zh) 2020-04-20 2021-04-20 用于治疗急性呼吸窘迫综合征的组合物和方法

Country Status (8)

Country Link
US (1) US20230192881A1 (https=)
EP (1) EP4138912A4 (https=)
JP (1) JP2023523096A (https=)
CN (1) CN115697410A (https=)
AU (1) AU2021261060A1 (https=)
CA (1) CA3174429A1 (https=)
IL (1) IL297363A (https=)
WO (1) WO2021212222A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020149518A1 (ko) * 2019-01-14 2020-07-23 주식회사 에이아이인사이트 안저영상 자동판독을 위한 딥러닝 아키텍처 시스템 및 딥러닝 아키텍쳐 시스템을 이용한 안저영상 자동판독 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150110811A1 (en) * 2013-10-22 2015-04-23 Novimmune S.A. Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of tlr4 ligands and other biomarkers
US20170038381A1 (en) * 2015-08-06 2017-02-09 Novimmune Sa Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders
US20180094052A1 (en) * 2016-09-30 2018-04-05 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriasis with Anti-IL23 Specific Antibody

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674884B2 (en) * 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
US7312320B2 (en) * 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
JP2010526868A (ja) * 2007-05-14 2010-08-05 ノビミューン エスアー 改変されたエフェクター機能を有するＦｃ受容体結合ポリペプチド
US8734790B2 (en) * 2011-01-10 2014-05-27 Novimmune Sa Anti-TLR4 antibodies and methods of use thereof
HUE037613T2 (hu) * 2012-03-29 2018-09-28 Novimmune Sa Anti-TLR4 antitestek és azok felhasználása

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150110811A1 (en) * 2013-10-22 2015-04-23 Novimmune S.A. Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of tlr4 ligands and other biomarkers
US20170038381A1 (en) * 2015-08-06 2017-02-09 Novimmune Sa Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders
US20180094052A1 (en) * 2016-09-30 2018-04-05 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriasis with Anti-IL23 Specific Antibody

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
E MONNET等: "Evidence of NI-0101 pharmacological activity, an anti-TLR4 antibody, in a randomized phase I dose escalation study in healthy volunteers receiving LPS", CLINICAL PHARMACOLOGY AND THERAPEUTICS, vol. 101, no. 2, 5 October 2016 (2016-10-05), pages 200 - 208, XP055864561, DOI: 10.1002/cpt.522 *
K A SHIREY等: "Novel strategies for targeting innate immune responses to influenza", MUCOSAL IMMUNOL OGY, vol. 9, no. 5, 27 January 2016 (2016-01-27), pages 1173 - 1182, XP055420280, DOI: 10.1038/mi.2015.141 *
SHUJUN ZHOU等: "Effect of TLR4/MyD88 signaling pathway on sepsis-associated acute respiratory distress syndrome in rats, via regulation of macrophage activation and inflammatory response", EXPERIMENT AND THERAPEUTIC MEDICINE, vol. 15, no. 4, 30 January 2018 (2018-01-30), pages 3376 *
YUMIKO IMAI等: "Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury", CELL, vol. 133, no. 2, 18 April 2008 (2008-04-18), pages 235 - 249, XP093148312, DOI: 10.1016/j.cell.2008.02.043 *

Also Published As

Publication number Publication date
JP2023523096A (ja) 2023-06-01
EP4138912A4 (en) 2024-08-07
CA3174429A1 (en) 2021-10-28
WO2021212222A1 (en) 2021-10-28
IL297363A (en) 2022-12-01
EP4138912A1 (en) 2023-03-01
AU2021261060A1 (en) 2022-11-17
US20230192881A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
US10584172B2 (en) Humanized monoclonal antibodies and methods of use
JP5775615B2 (ja) アルファ−４−ベータ−７ヘテロ二量体特異的アンタゴニスト抗体
JP2022023051A (ja) 瘻孔を伴うクローン病の治療用ベドリズマブ
EP3033356B1 (en) Antibodies against frizzled proteins and methods of use thereof
KR102550991B1 (ko) 아밀로이드 베타에 대한 항체
EP3511344A1 (en) Neutralizing antibodies and methods of use thereof
JP2023018064A (ja) 抗ｆａｍ１９ａ５抗体及びその用途
CN102046199A (zh) 使用抗mif抗体的治疗方法
TWI867422B (zh) 用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法
NO334834B1 (no) Anti-alfavbeta6-antistoff, celle som produserer slikt antistoff, samt anvendelse av antistoffet for fremstilling av medikamenter
KR20110018365A (ko) 베타7 인테그린 길항제를 이용한 위장 염증 장애의 치료를 평가하기 위한 바이오마커의 용도
AU2021213403B2 (en) Anti-αvβ8 integrin antibodies for use in treating kidney disease
CN109734807A (zh) 施用β7整联蛋白拮抗剂的方法
JP2020019824A (ja) 抗ｔｌｒ４抗体およびその使用方法
CN115697410A (zh) 用于治疗急性呼吸窘迫综合征的组合物和方法
US20250171537A1 (en) Method of treating disease using anti-cd47 x anti-mesothelin antibodies as a sole agent and in combination with anti-pd-1 antibodies
AU2016303033A1 (en) Methods and compositions for identifying patient populations for diagnosis and treatment of TLR4-dependent disorders
US20240376225A1 (en) Cd21 antibodies and uses thereof
TW202323290A (zh) 涉及il-18抗體之方法及治療
KR20240134909A (ko) Il-18에 대한 항체를 포함하는 성인-발병성 스틸병 및 전신-발병성 소아 특발성 관절염에 대한 방법 및 치료
TW202325730A (zh) 涉及ｉｌ－１８抗體之成人史迪爾氏症（ｓｔｉｌｌ＇ｓ ｄｉｓｅａｓｅ）及全身性幼年特發性關節炎之方法及治療
CN117561078A (zh) 用于评价发展急性covid-19和急性后covid-19的风险的生物标志物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination